Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

867
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
867
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

824
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
824
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

1.3K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.3K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

450
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
450

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct Oral Anticoagulant Type and Dose in Atrial Fibrillation With Decompensated Cirrhosis: A Propensity-Matched Analysis.

Gastro hep advances·2026
Same author

Do hepatic and biliary functional data from gadoxetate-enhanced MRI add value in predicting outcomes in primary sclerosing cholangitis (PSC)?

European radiology·2026
Same author

The Nutrition Landscape in Chronic Liver Disease.

Digestive diseases and sciences·2026
Same author

Vitamin B6 predicts poor outcomes in geographically distinct populations with primary sclerosing cholangitis.

Journal of hepatology·2026
Same author

Compositional and functional differences of gut microbiome and metabolome inform pathogenesis of cholestatic liver disease.

Gut microbes·2026
Same author

Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America-A 5-Year Analysis.

Liver international : official journal of the International Association for the Study of the Liver·2026

Related Experiment Video

Updated: Mar 9, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

941

The Microbiome and Primary Sclerosing Cholangitis.

Ahmad H Ali1, Elizabeth J Carey1, Keith D Lindor1

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona.

Seminars in Liver Disease
|December 21, 2016
PubMed
Summary

Primary sclerosing cholangitis (PSC), a chronic liver disease, may be influenced by gut bacteria. Research explores fecal microbiota transplantation and probiotics as potential treatments for PSC.

More Related Videos

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

31.4K
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.6K

Related Experiment Videos

Last Updated: Mar 9, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

941
Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

31.4K
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.6K

Area of Science:

  • Gastroenterology and Hepatology
  • Microbiology
  • Immunology

Background:

  • Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with poor prognosis, often progressing to liver failure and cancer.
  • PSC frequently co-occurs with inflammatory bowel disease (IBD), particularly ulcerative colitis.
  • The exact causes of PSC are unknown, but the gut microbiota is increasingly implicated in its development.

Purpose of the Study:

  • To review the current understanding of the intestinal microbiota's role in the pathogenesis of PSC.
  • To discuss emerging therapeutic strategies targeting the gut microbiome for PSC treatment.

Main Methods:

  • Review of existing literature on PSC and the gut microbiome.
  • Analysis of studies investigating antibiotic therapies, fecal microbiota transplantation (FMT), and probiotics in PSC patients.

Main Results:

  • Evidence suggests a significant link between alterations in the gut microbiota and PSC.
  • Antibiotic treatments have shown some promising outcomes in preliminary studies.
  • Fecal microbiota transplantation and probiotics are under investigation as novel therapeutic avenues.

Conclusions:

  • The intestinal microbiota is a key area of interest for understanding PSC etiology.
  • Targeting the gut microbiome holds potential for future PSC therapies, including FMT and probiotics.